Clinical Research Directory
Browse clinical research sites, groups, and studies.
ANG-First Trial (Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery)
Sponsor: University of Maryland St. Joseph Medical Center
Summary
The purpose of this research is to evaluate the use of Angiotensin II in patients with low blood pressure post-surgery. Your information will be collected for 28 days post the procedure and initiation of the study drug to assess for safety events and complications.
Official title: Angiotensin II as First-Line Vasopressor Therapy in Cardiac Surgery (ANG-First Trial)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2025-05-06
Completion Date
2026-02
Last Updated
2025-12-22
Healthy Volunteers
Yes
Interventions
Angiotensin II
Angiotensin II: Starting dose of 2.5 ng/kg/min administered IV; may dose escalate up to 80 ng/kg/min in order to achieve a MAP of 65 mmHg or higher in the first 3 hours. After 3 hours, may escalate dose up to 40 ng/kg/min in order to achieve a MAP of 65 mmHg. Dose titration in increments of 10 ng/kg/min every 2 minutes.
Locations (1)
University of Maryland St. Joseph Medical Center
Towson, Maryland, United States